
    
      In patients with type 2 diabetes mellitus being treated with sitagliptin, efficacy and safety
      of DS-8500a are to be evaluated after 28-day multiple oral administration of DS-8500a at 25
      or 75 mg, in a double-blind, placebo-controlled, parallel-group comparison study.
    
  